Taube et al. [41] demonstrated that PD-L1 expression on TC was a predictive biomarker for anti-PD-1 drug Nivolumab in 41 patients with advanced solid tumors, including 16 melanoma, 12 NSCLC, 6 CRC, 5 RCC, and 2 patients with castration-resistant prostate carcinoma. This evidence concerns the gene CD274 and melanoma.